<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36790644</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1565</StartPage><EndPage>1572</EndPage><MedlinePgn>1565-1572</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06539-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Disturbed lipid metabolism was observed in systemic lupus erythematosus (SLE) patients. This study aimed to evaluate the relationships between dyslipidemia and visceral organ involvement, disease severity, inflammatory factors, and drug intake in SLE patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Inpatients with SLE (n = 105) and healthy controls (HC) (n = 75) were recruited in this study. Clinical and laboratory data were collected from patient records. The concentrations of tumor necrosis factor receptors superfamily member1A (TNFRSF1A), member1B (TNFRSF1B) and adipokine angiopoietin-like 4 (ANGPTL4) in plasma were measured by ELISA.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Compared to HC, serum levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and apolipoprotein B (ApoB) were significantly increased, while high-density lipoprotein (HDL) and apolipoprotein A1 (ApoA1) were decreased in SLE patients. Patients with higher disease activity and renal damage suffered from more severe dyslipidemia. Renal functional parameters were closely correlated with serum lipid levels. Inflammatory factors were associated with dyslipidemia. The levels of TNFRSF1A and TNFRSF1B were obviously increased and associated with kidney involvement in SLE patients. Patients with high-dose glucocorticoid intake showed more severe dyslipidemia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Attention should be paid to the dyslipidemia of SLE. Dyslipidemia is associated with inflammation and organ involvement in SLE. These findings might provide a new strategy for the treatment of SLE. Key Points &#x2022; Serum levels of TG, TC, LDL, and ApoB were significantly increased, while HDL and ApoA1 were decreased in SLE patients. &#x2022; Patients with higher disease activity and renal damage suffered from more severe dyslipidemia. Renal functional parameters and inflammatory factors were closely correlated with serum lipid levels. &#x2022; Patients with high-dose glucocorticoid intake showed more severe dyslipidemia. &#x2022; These findings might provide a new strategy for the treatment of SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Saisai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Zhuoya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yiyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Genhong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China. mxlay1984@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huayong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0125-2755</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China. huayong.zhang@nju.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 81901644</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>YKK19051</GrantID><Agency>Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health</Agency><Country/></Grant><Grant><GrantID>2022-YXZX-MY-05</GrantID><Agency>fundings for Clinical Trial from the affiliated Drum Tower Hospital, Medical School of Nanjing University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001055">Apolipoproteins B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001055" MajorTopicYN="N">Apolipoproteins B</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease activity</Keyword><Keyword MajorTopicYN="N">Dyslipidemia</Keyword><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">Renal damage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36790644</ArticleId><ArticleId IdType="pmc">PMC10203001</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06539-2</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06539-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mohamed A, Chen Y, Wu H, Liao J, Cheng B, Lu Q. Therapeutic advances in the treatment of SLE. Int Immunopharmacol. 2019;72:218&#x2013;223. doi: 10.1016/j.intimp.2019.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.03.010</ArticleId><ArticleId IdType="pubmed">31002998</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro LL, Lanna CCD, Ribeiro ALP, Telles RW. Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37:2693&#x2013;2698. doi: 10.1007/s10067-018-4169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4169-0</ArticleId><ArticleId IdType="pubmed">29948349</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito M, Yajima N, Yanai R, Tsubokura Y, et al. Prevalence and treatment conditions for hypertension and dyslipidaemia complicated with systemic lupus erythematosus: a multi-centre cross-sectional study. Lupus. 2021;30:1146&#x2013;1153. doi: 10.1177/09612033211006790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211006790</ArticleId><ArticleId IdType="pubmed">33794706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenbecher C, Eichelmann F, Toledo E, et al. Lipid profiles and heart failure risk: results from two prospective studies. Circ Res. 2021;128:309&#x2013;320. doi: 10.1161/CIRCRESAHA.120.317883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317883</ArticleId><ArticleId IdType="pmc">PMC7864881</ArticleId><ArticleId IdType="pubmed">33272114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol. 2020;18:549&#x2013;565. doi: 10.2174/1570161118666191227101636.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161118666191227101636</ArticleId><ArticleId IdType="pubmed">31880245</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol. 2021;52:693&#x2013;701. doi: 10.1159/000518456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518456</ArticleId><ArticleId IdType="pubmed">34569479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasturi S, Sammaritano LR. Corticosteroids in lupus. Rheum Dis Clin North Am. 2016;42:47&#x2013;62. doi: 10.1016/j.rdc.2015.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2015.08.007</ArticleId><ArticleId IdType="pubmed">26611550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes PC, Fuhrmann A, Sereno J, Espinoza DO, et al. Short and long term in vivo effects of cyclosporine A and sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. Metabolism. 2014;63:702&#x2013;715. doi: 10.1016/j.metabol.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.02.004</ArticleId><ArticleId IdType="pubmed">24656168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tholking G, Schulte C, el Jehn U, al, The tacrolimus metabolism rate and dyslipidemia after kidney transplantation. J Clin Med. 2021;10:3066. doi: 10.3390/jcm10143066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10143066</ArticleId><ArticleId IdType="pmc">PMC8306747</ArticleId><ArticleId IdType="pubmed">34300232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yu H, He J. Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases. Discov Med. 2020;30:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">33357362</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1998;8:586&#x2013;595. doi: 10.1191/096120399680411317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399680411317</ArticleId><ArticleId IdType="pubmed">10568894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630&#x2013;640. doi: 10.1002/art.1780350606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol. 2017;8:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376873</ArticleId><ArticleId IdType="pubmed">29357123</ArticleId></ArticleIdList></Reference><Reference><Citation>Thongnak L, Pongchaidecha A, Lungkaphin A. Renal lipid metabolism and lipotoxicity in diabetes. Am J Med Sci. 2020;359:84&#x2013;99. doi: 10.1016/j.amjms.2019.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2019.11.004</ArticleId><ArticleId IdType="pubmed">32039770</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76:265&#x2013;281. doi: 10.1053/j.ajkd.2019.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Asanuma Y, Chung CP, Oeser A, el Shintanial, A. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol. 2006;33:539&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">16463434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Pedrera C, Aguirre MA, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. 2010;2010:607084. doi: 10.1155/2010/607084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/607084</ArticleId><ArticleId IdType="pmc">PMC2948929</ArticleId><ArticleId IdType="pubmed">20936125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952&#x2013;964. doi: 10.1016/j.jhep.2011.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2011.08.025</ArticleId><ArticleId IdType="pubmed">22173168</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal W, Haghi M, Hasni SA, Newman KA. Lupus hepatitis, more than just elevated liver enzymes. Scand J Rheumatol. 2020;49:427&#x2013;433. doi: 10.1080/03009742.2020.1744712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2020.1744712</ArticleId><ArticleId IdType="pubmed">32942921</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi H, Higashihara T, Inagi R. Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients. 2019;11:1664. doi: 10.3390/nu11071664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11071664</ArticleId><ArticleId IdType="pmc">PMC6682887</ArticleId><ArticleId IdType="pubmed">31330812</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CJ. Lipid metabolism in inflammation and immune function. Nutrients. 2022;14:1414. doi: 10.3390/nu14071414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14071414</ArticleId><ArticleId IdType="pmc">PMC9002396</ArticleId><ArticleId IdType="pubmed">35406026</ArticleId></ArticleIdList></Reference><Reference><Citation>Albar Z, Wijaya LK. Is there a relationship between serum C-reactive protein level and dyslipidaemia in systemic lupus erythematosus? Acta Med Indones. 2006;38:23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16479028</ArticleId></ArticleIdList></Reference><Reference><Citation>Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA, Orekhov AN. Anti-inflammatory therapy for atherosclerosis: focusing on cytokines. Int J Mol Sci. 2021;22:7061. doi: 10.3390/ijms22137061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137061</ArticleId><ArticleId IdType="pmc">PMC8269273</ArticleId><ArticleId IdType="pubmed">34209109</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuko K. Angiopoietin-like 4: a molecular link between insulin resistance and rheumatoid arthritis. J Orthop Res. 2017;35:939&#x2013;943. doi: 10.1002/jor.23507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jor.23507</ArticleId><ArticleId IdType="pubmed">28004425</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryal B, Price NL, Suarez Y, Fernandez-Hernando C. ANGPTL4 in metabolic and cardiovascular disease. Trends Mol Med. 2019;25:723&#x2013;734. doi: 10.1016/j.molmed.2019.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.05.010</ArticleId><ArticleId IdType="pmc">PMC6779329</ArticleId><ArticleId IdType="pubmed">31235370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal SS, Ismahil MA, el Goelal, M. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. Circulation. 2019;39:206&#x2013;221. doi: 10.1161/CIRCULATIONAHA.118.036065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036065</ArticleId><ArticleId IdType="pmc">PMC6322956</ArticleId><ArticleId IdType="pubmed">30586716</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewczas MA, Pavkov ME, el Skupienal, J. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25:805&#x2013;813. doi: 10.1038/s41591-019-0415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0415-5</ArticleId><ArticleId IdType="pmc">PMC6508971</ArticleId><ArticleId IdType="pubmed">31011203</ArticleId></ArticleIdList></Reference><Reference><Citation>Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 2014;43:75&#x2013;102. doi: 10.1016/j.ecl.2013.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecl.2013.10.005</ArticleId><ArticleId IdType="pmc">PMC3942672</ArticleId><ArticleId IdType="pubmed">24582093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>